The 30 linked references in paper D. Goryachev V., M. Telnykh Yu, Д. Горячев В., М. Тельных Ю. (2018) “Планирование регистрационной программы исследований препаратов базисной противовоспалительной терапии ревматоидного артрита // Planning of a Clinical Data Registry for Basic Anti-Inflammatory Drugs for the Treatment of Rheumatoid Arthritis” / spz:neicon:vedomostincesmp:y:2018:i:4:p:238-245

  1. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66(1):34–45. https://doi.org/10.1136/ ard.2005.044354
  2. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of international task force. Ann Rheum Dis. 2010;69(4):631–7. https://doi.org/10.1136/ard.2009.123919
  3. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with diseasemodifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 2004;50(7):2072–81. https://doi. org/10.1002/art.20351
  4. Горячев ДВ, Тельных МЮ, Бунятян НД. Регуляторные подходы к оценке биоаналогов для лечения ревматических заболеваний. Ведомости Научного Центра экспертизы средств медицинского применения. 2017;7(3):155–63. [Goryachev DV, Telnykh MYu, Bunyatyan ND. Regulatory approaches to evaluation of biosimilars for treatment of rheumatic diseases. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2017;7(3):155–63 (In Russ.)]. https://doi.org/10.30895/1991-29192017-7-3-155-163
  5. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. https:// doi.org/10.1002/art.27584
  6. Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009;60(8):2262–71. https://doi.org/10.1002/art.24661
  7. Aletaha D, Funovits J, Ward MM, Smolen JS, Kvien TK. Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline. Arthritis Rheum. 2009;61(3):313–20. https://doi.org/10.1002/art.24282
  8. Wit MP, Smolen JS, Gossec L, van der Heijde D. Treating rheumatoid arthritis to target: the patient version of the international recommendations. Ann Rheum Dis. 2011;70:891–5. https://doi. org/10.1136/ard.2010.146662
  9. Fautrel B, Guillemin F, Meyer O, de Bandt M, Berthelot JM, Flipo RM, et al. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists’ preferences. Arthritis Rheum. 2009;61(4):425–34. https://doi.org/10.1002/ art.24588
  10. Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Martin Mola E, Pedersen R, et al. Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. Ann Rheum Dis. 2009;68(7):1113–8. https://doi.org/10.1136/ard.2008.094375
  11. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008;67(10):1360–4. https://doi.org/10.1136/ ard.2008.091454
  12. Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis. 2007;66(Suppl. 3):iii56-iii60. https://doi.org/10.1136/ ard.2007.078360
  13. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology / European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573–86. https:// doi.org/10.1002/art.30129
  14. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52(9):2625–36. https://doi.org/10.1002/art.21235
  15. Heiberg T, Kvien TK, Mowinckel P, Aletaha D, Smolen JS, Hagen KB. Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(7):967–71. https://doi.org/10.1136/ ard.2007.077503
  16. Smolen JS, Aletaha D. Activity assessments in rheumatoid arthritis. Curr Opin Rheumatol. 2008;20(3):306–13. https://doi.org/10.1097/ BOR.0b013e3282fbd382
  17. Soubrier M, Dougados M. Selecting criteria for monitoring patients with rheumatoid arthritis. Joint Bone Spine. 2005;72(2):129–34. https://doi.org/10.1016/j.jbspin.2004.05.007
  18. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum. 2006;54(9):2784–92. https://doi.org/10.1002/art.22052
  19. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford). 2007;46(2):342–9. https://doi.org/10.1093/rheumatology/kel237
  20. Helm-van Mil AH, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR, et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum. 2008;58(8):2241–7. https://doi.org/10.1002/art.23681
  21. Gulfe A, Aletaha D, Saxne T, Geborek P. Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents. BMC Musculoskelet Disord. 2009;10:41. https://doi.org/10.1186/1471-2474-10-41
  22. Smolen JS, Aletaha D, Grisar JC, Stamm TA, Sharp JT. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis. 2010;69(6):1058– 64. https://doi.org/10.1136/ard.2009.114652
  23. Schoels M, Kapral T, Stamm T, Smolen JS, Aletaha D. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study. Ann Rheum Dis. 2007;66(8):1059– 65. https://doi.org/10.1136/ard.2006.061820
  24. Kapral T, Dernoschnig F, Machold KP, Stamm T, Schoels M, Smolen JS, et al. Remission by composite scores in rheumatoid arthritis: are ankles and feet important? Arthritis Res Ther. 2007;9(4):R72. https:// doi.org/10.1186/ar2270
  25. Suresh E, Lambert CM. Combination treatment strategies in early rheumatoid arthritis. Ann Rheum Dis. 2005;64(9):1252–6. https:// doi.org/10.1136/ard.2004.032219
  26. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762–84. https://doi.org/10.1002/art.23721
  27. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8. https:// doi.org/10.1136/ard.2010.138461
  28. Garnero P, Landewe R, Boers M, Verhoeven A, van der Linden S, Christgau S, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum. 2002;46(11):2847–56. https://doi.org/10.1002/ art.10616
  29. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum. 2005;52(1):36–41. https://doi.org/10.1002/ art.20716
  30. Wolfe F, Rasker JJ, Boers M, Wells GA, Michaud K. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum. 2007;57(6):935–42. https://doi. org/10.1002/art.22895 Статья поступила 14.06.2018